EarningsQ2 2026 Earnings Report

Cigna (CGN) Q2 2026 Earnings Report

0 Followers

Previous Report: Q1 2026

CH:CGN Q2 2026 EPS Results

Actual EPSCHF6.45

Consensus EPSCHF6.30

Beat/MissBeat by +CHF0.15

One Year Ago EPSCHF5.97

CH:CGN Q2 2026 Revenue Results

Actual RevenueCHF59.39B

Expected RevenueCHF58.19B

Beat/MissBeat by +CHF1.21B

YoY Revenue Growth+6.50%

Earnings Announcement Details

QuarterQ2 2026

Date07/30/2026

TimeBefore Open

Conference CallThursday, July 30, 2026

CH:CGN Upcoming Earnings

Cigna's next earnings date is estimated for November 5, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

CH:CGN Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Jul 30, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed strong operational and financial momentum driven by specialty drug growth, Evernorth and Cigna Healthcare outperformance, AI-enabled clinical initiatives with measurable outcomes, solid revenue and EPS beats, and an upgraded full-year EPS outlook. Offsetting items include PBS earnings pressure from transition investments and economic shifts due to biosimilars, moderating GLP-1 utilization, persistently elevated medical cost trends, IDR-related affordability concerns, and one-time special charges. Overall, the positive drivers (revenue growth, margin gains in Specialty, upgraded guidance, retention/new-business strength, AI initiatives) materially outweigh the manageable challenges described.

Company Guidance

Cigna raised its full‑year 2026 adjusted EPS outlook to at least $30.45 (Q2 adjusted EPS $7.78; Q2 adjusted after‑tax earnings $2.1B) on total Q2 revenues of $71.7B; segment guidance includes Evernorth full‑year pretax adjusted earnings of at least $6.9B (Q2 Evernorth revenues $61.5B; Q2 pretax adj earnings $1.7B; Specialty & Care Q2 pretax adj earnings $1.1B, +22% y/y; PBS Q2 pretax adj earnings $609M) and Cigna Healthcare full‑year pretax adjusted earnings of at least $4.55B (Q2 revenues $11.8B; Q2 pretax adj earnings $1.3B). Management reiterated full‑year medical care ratio guidance (Q2 MCR 84.5%) and expects Q3 MCR slightly above Q2, second‑half adjusted EPS to be split roughly evenly between Q3 and Q4, and Cigna Healthcare’s Q3 pretax adjusted earnings to be over 60% of second‑half earnings. Capital/cash metrics: Q2 operating cash flow in line with expectations, full‑year operating free cash flow ~ $9B (back‑half weighted), debt‑to‑capitalization 42.8% at June 30 (targeting ~40% year‑end), repurchased ~900k shares for ~$250M in Q2; Q2 after‑tax special items were $153M ($0.58/sh).

Strong Q2 Financial Results

Total revenues of $71.7 billion and adjusted earnings per share of $7.78 in Q2; adjusted after-tax earnings of $2.1 billion for the quarter. Company delivered results ahead of expectations across the enterprise.

Raised Full-Year Guidance

Increased full-year 2026 adjusted earnings per share outlook to at least $30.45, reflecting strong first-half performance while maintaining a prudent view of the environment.

Evernorth Revenue Growth and Specialty Strength

Evernorth revenues grew 6% year-over-year to $61.5 billion; pretax adjusted earnings for Evernorth were $1.7 billion. Specialty & Care Services delivered pretax adjusted earnings of $1.1 billion, up 22% year-over-year, driven by specialty utilization growth, stronger biosimilar and specialty-generic adoption and operating efficiencies.

Cigna Healthcare Growth and Profitability

Cigna Healthcare revenues grew 10% year-over-year to $11.8 billion and pretax adjusted earnings grew 17% year-over-year to $1.3 billion. Medical care ratio (MCR) was 84.5% for the quarter, slightly better than expectations. U.S. employer membership growth and disciplined pricing contributed to results.

Rapid Adoption of Biosimilars / Specialty Generics

Faster-than-expected adoption of biosimilars and specialty generics improved affordability and contributed favorably to earnings; specialty generic penetration exceeded 80% for newer products in the quarter.

AI and Technology Initiatives Producing Measurable Outcomes

New programs (Pharmacy Forward, AI-enabled care coordination) expected to cut time-to-therapy in half and reduce clinician documentation time by up to 50%. Predictive/AI models can expand personalized clinical support to ~20% more customers; customers engaging in programs reduce medical costs by ~ $2,000 per year on average and have seen a 42% reduction in avoidable inpatient stays.

Strong PBM Retention and Selling Season Momentum

Pharmacy Benefit Services closed 2026 with over 97% retention and preliminary 2027 indicators also mid-90s+; total new business secured for 2027 is above the prior two selling seasons combined, indicating strong pipeline momentum for PBS and Signature interest.

Capital Management and Share Repurchases

Repurchased ~900,000 shares for approximately $250 million in Q2. Debt-to-capitalization was 42.8% as of June 30 with expectation to finish the year closer to 40%. Company expects approximately $9 billion of operating free cash flow for the year, mostly back-half weighted.

CH:CGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 05, 2026	2026 (Q3)	6.24 / -	6.495	―
Jul 30, 2026	2026 (Q2)	6.30 / 6.45	5.973	8.06% (+0.48)
Apr 30, 2026	2026 (Q1)	6.30 / 6.46	5.591	15.58% (+0.87)
Feb 05, 2026	2025 (Q4)	6.54 / 6.70	5.508	21.69% (+1.19)
Oct 30, 2025	2025 (Q3)	6.34 / 6.50	6.23	4.26% (+0.27)
Jul 31, 2025	2025 (Q2)	5.94 / 5.97	5.574	7.14% (+0.40)
May 02, 2025	2025 (Q1)	5.27 / 5.59	5.367	4.17% (+0.22)
Jan 30, 2025	2024 (Q4)	6.49 / 5.51	5.633	-2.21% (-0.12)
Oct 31, 2024	2024 (Q3)	6.00 / 6.23	5.616	10.93% (+0.61)
Aug 01, 2024	2024 (Q2)	5.33 / 5.57	5.085	9.62% (+0.49)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed